Background and objectives AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-tocreatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFR CrCyC ), as risk factors for AKI in elderly individuals.
Introduction
Community-acquired AKI is an increasingly common reason for hospital admissions in the United States over the past decade (1) . Patients hospitalized for AKI are at higher risk of developing ESRD and death (2, 3) . In addition, 46% of individuals who develop AKI will not fully recover and will be left with CKD, and 58% of patients will be hospitalized again within 1 year (1, 2) .
Because older persons are at higher risk for AKI (4), identifying AKI risk factors among older persons is particularly important. In a prior publication from the Cardiovascular Health Study (CHS), patient demographics (older age, male sex, nonwhite race,), cardiovascular risk factors (serum creatinine, diabetes, hypertension, current smoking), inflammatory biomarkers (C-reactive protein, fibrinogen, albumin, white blood cell count), and subclinical cardiovascular disease (low ankle-arm index, common and internal carotid intima-media thickness) were identified as risk factors for AKI (5) . The urine albumin-to-creatinine ratio (UACR) was not evaluated in this prior analysis.
Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone that is associated with increased risks of cardiovascular disease and progression to ESRD (6, 7) . Recent studies suggest that high circulating FGF-23 concentrations may also be due in part to tubular FGF-23 resistance, a state of tubular dysfunction that may also increase risk of AKI (8) . Although recent evidence suggests that FGF-23 is elevated at the time of AKI (9) , there are no studies of which we are aware that have evaluated whether circulating levels of FGF-23 are a risk factor for AKI incidence. Recent studies have also suggested that estimated GFR based on cystatin C or combined creatinine-cystatin C (eGFR CrCyC ) provides a more accurate measure of kidney function and may be more strongly associated with cardiovascular outcomes and all-cause mortality (10) (11) (12) (13) (14) (15) . Two recent studies of middle-aged individuals have also suggested that UACR may be associated with AKI; however, there are few studies that have focused exclusively on elderly individuals or evaluated all three biomarkers (FGF-23, UACR, and eGFR CrCyC ) (2, 3, 16) . We therefore evaluated FGF-23, UACR, and eGFR CrCyC , three different manifestations of kidney health, as risk factors for AKI hospitalizations in the CHS, a community-dwelling population of older adults. We also evaluated whether the relationships were independent of one another.
Materials and Methods

Study Population
The CHS enrolled 5201 adults aged $65 into a prospective longitudinal cohort to evaluate risk factors for cardiovascular disease (17,18). Community participants were enrolled between 1989 and 1990 from four communities in the United States (Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania) using Medicare eligibility lists. An additional 687 African-American participants were enrolled between 1992 and 1993. Eligible participants had an expectation to remain in the geographic area for 3 years, had no history of cancer, and were able to provide written informed consent. Physical examinations were conducted annually through 1998-1999 and in [2005] [2006] . Telephone interviews took place semiannually from 1998 to 1999 and biannually thereafter. All participants provided research access to their complete medical record and Medicare billing claims in follow-up. UACR was measured at the 1996-1997 visit; therefore, this study was restricted to 3406 active enrollees at the 1996-1997 visit. Participants were excluded if samples were not available for FGF-23 measurement (n=69), serum creatinine (n=0), or cystatin C (n=0), or if urine was not available for UACR (n=92). Enrollees with prior hospitalizations with AKI between 1989 and 1996 were excluded from the analysis (n=4). The final analytic cohort for this analysis comprised 3241 individuals.
Outcome Measure
All administrative discharge summaries were retrieved for the entire CHS cohort from 1996 through 2010. Hospitalization for AKI was defined by hospital discharge International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for AKI, including ICD-9-CM codes for 584 and 584.5-584.9 as the primary diagnosis (19) . ICD-9-CM codes for determining AKI have previously been shown to provide very high specificity (97.7%) yet low sensitivity (35.4%) (19) .
Exposure Variables
Fasting blood specimens collected in 1996-1997 were collected in EDTA and immediately stored at 270°C. Samples were thawed in 2010 for measurement of FGF-23 (RU/ml). FGF-23 was measured using a C-terminal ELISA kit (Immutopics International, San Clemente, CA) (20) . The intra-and interassay reliability was measured with coefficients of variation ranging from 7.4% to 10.6%.
A random urine sample obtained from each participant during the same visit was used to measure UACR. Urine albumin was measured by nephelometry using the Array 360 CE Protein Analyzer (Beckman Instruments, Fullerton, CA). Urinary creatinine was measured using a Kodak Ektachem 700 Analyzer (Eastman Kodak Company, Rochester, NY). UACR was calculated in milligrams per gram (21) .
The colorimetric method was also used to measure serum creatinine (milligrams per decaliter) using a Kodak Ektachem 700 Analyzer (Eastman Kodak Company). The coefficient of variation for creatinine among monthly controls was 1.94 (1.16, 3.60%). Serum creatinine was calibrated as previously described (22, 23) . Serum cystatin C concentrations were measured using a BN II nephelometer (Siemens, Munich, Germany). eGFR CrCyC was calculated using the recently published combined cystatin C and creatinine-based equation (10) .
Covariates
Model covariates were abstracted at the 1996-1997 study visit and included demographics (age, sex, race), prevalent cardiovascular disease (clinical diagnosis of prior stroke, heart failure, or coronary heart disease), and cardiovascular risk factors (smoking status [current, former, or never], hypertension [systolic BP $140 mmHg, diastolic BP $90 mmHg, or use of antihypertensive medications], diabetes [fasting glucose $126 mg/dl or use of oral hypoglycemic medications or insulin], total cholesterol, and high sensitivity C-reactive protein).
Statistical Analyses
Because many prior papers in other cohorts and several prior manuscripts from CHS have described characteristics by levels of eGFR CrCyC or UACR, we elected to describe the cohort by FGF-23 levels. Because there are no established clinical cutpoints for FGF-23, participants were divided into quartiles of FGF-23 and the distribution of covariates across the FGF-23 groups was evaluated. Correlations between FGF-23, UACR, and eGFR CrCyC were calculated. Time at risk was defined as the elapsed time from the 1996-1997 examination until the first occurrence of AKI. Annual incidence rates for AKI were calculated as the number of events divided by the participants' total time at risk. Natural piecewise cubic spline functions were constructed for FGF-23, UACR, and eGFR CrCyC with prespecified knots placed at the quartiles of FGF-23, UACR, and eGFR CrCyC . Nested Cox proportional hazards models were used to estimate the relative hazard of AKI after adjustment for relevant confounding variables. Four sequential models were performed: (1) unadjusted; (2) adjusted for age, sex, and race; (3) additional adjustment for prevalent cardiovascular disease (history of stroke, heart failure, and coronary heart disease) and cardiovascular risk factors (hypertension, diabetes, current smoker, body mass index, total cholesterol, albumin, and C-reactive protein), and (4) eGFR CrCyC ($60 and ,60 ml/min per 1.73 m 2 ) and UACR ($30 and ,30 mg/g), and given the possibility of competing risk due to mortality, we also evaluated a composite outcome of AKI or death. To test for multicollinearity, we used the variance inflation factor (VIF) and interactions. The proportional hazards assumption was satisfied for all models (P.0.20). We conducted analyses using S-Plus (version 8.0; Tibco, Seattle, WA) and SPSS statistical software (version 16.0.2; SPSS, Inc., Chicago, IL). This research is in compliance with institutional review board approval and compliance with the Declaration of Helsinki.
Results
The mean age of the 3241 participants was 7865 years; 60% were women and 16% were African American. Median (interquartile range) values for FGF-23, UACR, and eGFR CrCyC were 70 RU/ml (53, 99), 8.88 mg/g (4.71, 20.47), and 71 ml/min per 1.73 m 2 (59, 83), respectively. Individuals in the highest quartile of FGF-23 values were older, were more likely to be women and less likely to be African American, were more likely to have a history of prior stroke, heart failure, or coronary heart disease, and had a higher prevalence of cardiovascular risk factors. eGFR CrCyC was lower and UACR higher in the higher quartiles of FGF-23 ( Table 1 ). The correlations were 0.20 between FGF23 and UACR, 20.41 between FGF-23 and eGFR CrCyC , and 20.19 between UACR and eGFR CrCyC (all P,0.01).
The median follow-up was 10.0 years (interquartile range, 5.7, 12.4), during which 119 participants were hospitalized with AKI. Individuals in the highest quartiles of FGF-23, UACR, and eGFR CrCyC had a higher incidence of AKI (Figure 1 ). Figure 2 demonstrates the unadjusted and adjusted splines relating FGF-23, UACR, and eGFR CrCyC with AKI.
After adjustment for demographic factors, higher FGF-23 was associated with a higher risk of AKI. After additional adjustment for cardiovascular risk factors and kidney-related factors, the second and fourth quartiles were associated with AKI in comparison with the first quartile. There was, however, attenuation after adjustment for UACR and eGFR CrCyC (Table 2) . Individuals in the highest two quartiles ($9.0 mg/g) of UACR were at higher risk of AKI in unadjusted and adjusted analyses (Table 2) , whereas individuals in the lowest two quartiles of eGFR CrCyC (,68 ml/min per 1.73 m 2 ) had a higher risk of AKI in both unadjusted and adjusted analyses (Table 2) .
When using clinical cutpoints, the unadjusted and fully adjusted hazard ratios for eGFR CrCyC ,60 ml/min per 1.73 m 2 compared with $60 ml/min per 1.73 m 2 were 2.47 (95% confidence interval [95% CI], 1.70 to 3.58) and 1.65 (95% CI, 1.10 to 2.48), respectively, whereas the unadjusted and fully adjusted hazard ratios for UACR $30 mg/g compared with ,30 mg/g were 3.06 (95% CI, 2.04 to 4.60) and 1.86 (95% CI, 1.20 to 2.89), respectively. We tested for colinearity using VIFs. The VIFs were 1.32 for FGF-23, 1.46 for eGFR CrCyC , and 1.25 for UACR; therefore, we had no concerns regarding colinearity. We found no interaction between FGF-23 and ACR (P=0.71) or FGF-23 and eGFR CrCyC (P=0.74). Lastly, we evaluated the composite outcome of either AKI or mortality. There were 2023 individuals who reached this outcome; after adjusting for demographics, cardiovascular risk factors, and kidney-related factors, the association with AKI in the second through fourth quartiles of FGF-23 (in comparison with the first quartile) were as follows: 1.07 (0.94, 1.23), 1.12 (0.98, 1.29) , and 1.57 (1.36, 1.81).
Discussion
In this study, we demonstrate that higher levels of FGF-23, UACR, and lower eGFR CrCyC were each independently associated with hospitalization for AKI in communitydwelling elderly individuals. These relationships remained significant after adjustment for demographic, cardiovascular risk factors, as well as each other. These results suggest that different measures of kidney health are all associated with risk of AKI.
Although FGF-23 measured within 24 hours of AKI diagnosis ($0.3 mg/dl or $50% increase in serum creatinine) has been linked to a higher risk of death or dialysis (9) , to our knowledge, this is the first study demonstrating an association between FGF-23 and hospitalization for AKI. FGF-23 is a phosphaturic hormone that regulates mineral homeostasis (7, 24) . Recent studies have suggested that FGF-23 is associated with incident cardiovascular disease, left ventricular hypertrophy (LVH), heart failure, progression of kidney disease, and mortality (6, 7, 25) . Therefore, FGF-23 may reflect severity of mineral metabolism risk factors or severity of cardiovascular disease, which in turn are risk factors for AKI.
The theoretical mechanism linking FGF-23 with AKI, through LVH and heart failure, is supported by animal models (26) . Mice injected with intravenous FGF-23 developed a significant increase in ventricular wall thickness after 40 mg/kg q8-hour injections for 5 days (26) . In Klotho-deficient mice (coreceptor binding protein for FGF-23), when FGF-23 was elevated, LVH was more likely present than controls (26) . Thus, high FGF-23 may result in LVH and heart failure, which in turn are risk factors for AKI.
We also recently demonstrated that high FGF-23 is associated with cardiovascular disease particularly when the We also confirmed that UACR and eGFR CrCyC were independently associated with AKI. A prior CHS analysis, lacking urine measures, demonstrated that higher serum creatinine increased the risk of AKI (5). James and colleagues demonstrated that creatinine-based eGFR and proteinuria were associated with AKI defined by administrative billing codes (3) . This Canadian population-based study leveraged a single-payer provincial system, but was restricted to 60% of the population with a urine dipstick measurement (average age 57 years) and only 7% had UACR measured. The Atherosclerosis Risk in Communities (ARIC) study (mean age 63 years) also utilized administrative billing codes to capture AKI hospitalizations and noted that both eGFR and UACR were risk factors for AKI in adjusted analyses (2) . The Chronic Kidney Disease Prognosis Consortium reported in a meta-analysis that eGFR and UACR were independently associated with incident AKI (appendix, Table 11 in Ganesvoort et al. [16] ) in the general population; similar results were noted in a stratified analysis by age groups (,65 and .65 years) (16) . We expand on results from these prior studies by using the combined cystatin C and serum creatinine eGFR CrCyC , and therefore providing a more accurate measure of eGFR both as the exposure variable as well as an adjustment variable (10) . We also focus exclusively on elderly individuals, the group at highest risk for AKI. Finally, we were able to adjust for a larger set of rigorously ascertained confounding variables in comparison with the CKD Prognosis Consortium.
There are several limitations to our analysis. First, our primary endpoint is hospitalization with AKI defined by ICD-9-CM administrative billing codes as the primary diagnosis. Using the gold standard of a 100% change in serum creatinine for AKI, ICD-9-CM codes for determining AKI were previously shown to provide very high specificity (97.7%) but low sensitivity (35.4%) (19) . A prior analysis from the CHS also confirmed the specificity of using ICD-9 codes for diagnosing AKI (5) . Therefore the results of these analyses can be generalized to patients with clinically recognized episodes of AKI requiring hospitalization, but it is uncertain whether they are generalizable to milder episodes of AKI. Other authors, however, have advocated use of these codes; for example, almost all prior studies evaluating this issue, including the US Renal Data System, the study from Alberta, Canada, and the ARIC study, used these methods to identify hospitalizations for AKI (1-3,5) . Second, although our study is generalizable to the white or African-American elderly populations in the United States, whether the results generalize to younger populations or other races or ethnicities is uncertain. Third, although we conducted thorough statistical adjustment for known risk factors, both unmeasured and residual confounding remain possibilities. Lastly, FGF-23 was only measured once, as opposed to serially, and UACR was measured using a random sample, rather than a morning sample. Both would most likely have led to misclassification of the exposure variable and dilution of the results to the null (29) . The strength of CHS, however, is that it is a large community-based cohort in elderly individuals, and has detailed ascertainment of risk factors at baseline and long-term follow-up to ascertain clinically important outcomes.
In summary, we report that elevated levels of FGF-23, UACR, and eGFR CrCyC are all associated with a higher risk of hospitalization for AKI among community-dwelling elderly individuals. If these results are confirmed, these measures may identify older persons at higher risk for AKI.
